<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002542</url>
  </required_header>
  <id_info>
    <org_study_id>MA12</org_study_id>
    <secondary_id>CAN-NCIC-MA12</secondary_id>
    <secondary_id>NCI-V93-0323</secondary_id>
    <secondary_id>CDR0000063224</secondary_id>
    <nct_id>NCT00002542</nct_id>
  </id_info>
  <brief_title>Tamoxifen in Treating Women With High-Risk Breast Cancer</brief_title>
  <official_title>DOUBLE-BLIND RANDOMIZED TRIAL OF TAMOXIFEN VERSUS PLACEBO IN PATIENTS WITH NODE POSITIVE BREAST CANCER WHO HAVE COMPLETED CMF, CEF OR AC ADJUVANT CHEMOTHERAPY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NCIC Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Canadian Cancer Trials Group</source>
  <brief_summary>
    <textblock>
      RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using
      tamoxifen may fight breast cancer by blocking the uptake of estrogen. Chemotherapy uses
      different ways to stop tumor cells from dividing so they stop growing or die.

      PURPOSE: Phase III trial to study the effectiveness of tamoxifen following surgery and
      chemotherapy in treating women who have stage I breast cancer at high risk of recurrence or
      stage II or stage III breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Compare the duration of overall survival and disease-free survival in
      premenopausal women with operable, high risk node negative or axillary node-positive breast
      cancer who have undergone complete surgical resection of all known disease by means of total
      or partial mastectomy, and have received standard adjuvant chemotherapy with
      cyclophosphamide, methotrexate, and fluorouracil (CMF), cyclophosphamide, epirubicin, and
      fluorouracil (CEF), or doxorubicin and cyclophosphamide (AC) followed by either daily
      tamoxifen for 5 years or placebo. II. Compare the short- and long-term toxicity in patients
      receiving tamoxifen versus placebo. III. Monitor follicle-stimulating hormone, luteinizing
      hormone, and estradiol levels, and determine whether overall survival and disease-free
      survival are affected by hormonal or menopausal status during or at completion of adjuvant
      chemotherapy or during or after tamoxifen or placebo treatment in these patients.

      OUTLINE: This is a randomized, double blind study. Patients are stratified by adjuvant
      chemotherapy regimen (cyclophosphamide, epirubicin, and fluorouracil vs cyclophosphamide,
      methotrexate, and fluorouracil vs cyclophosphamide and doxorubicin), hormone receptor status
      (ER and/or PR positive vs ER and PR negative), number of positive nodes (1-3 vs 4-9 vs 10 or
      more), and participating institution. Patients receive one of three regimens of adjuvant
      chemotherapy at the discretion of the investigator. Regimen A: Patients receive oral
      cyclophosphamide on days 1-14 and epirubicin IV and fluorouracil IV on days 1 and 8. Courses
      repeat every 28 days for a total of 6 courses. Following chemotherapy, lumpectomy patients
      receive local radiotherapy daily for 5 weeks. Regimen B: Patients receive oral
      cyclophosphamide on days 1-14 or cyclophosphamide IV on day 1 and 8, methotrexate on days 1
      and 8, and fluorouracil IV on days 1 and 8. Courses repeat every 28 days for a total of 6
      courses. Concurrent with or following chemotherapy, lumpectomy patients receive local
      radiotherapy daily for 5 weeks. Regimen C: Patients receive doxorubicin IV and
      cyclophosphamide IV every 21 days for a total of 4 courses. Following chemotherapy,
      lumpectomy patients receive local radiotherapy daily for 5 weeks. Patients are then
      randomized to receive either oral tamoxifen or a placebo once daily for 5 years, beginning
      within 6 weeks of completion of chemotherapy. Treatment continues in the absence of disease
      progression or unacceptable toxicity. Patients are followed for survival.

      PROJECTED ACCRUAL: A total of 800 patients will be accrued for this study over 4 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 1993</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CMF regimen</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epirubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tamoxifen citrate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Adenocarcinoma of the breast with 1 or more histologically proven
        positive axillary nodes OR Adenocarcinoma of the breast with negative axillary nodes or
        adverse prognostic factors such that the patient is at high risk for recurrence and node
        negative lesion is characterized by the following features: Tumor at least 1 cm Poorly
        differentiated, SBR grade III, or MSBR grade V and/or lymphatic/vascular invasion
        Pathologic review by experienced breast pathologist recommended if grade is unspecified and
        lymphatic/vascular invasion is absent Disease considered potentially curable and treated by
        1 of the following: Complete surgical removal of the breast plus axillary node dissection
        Partial surgical removal of the breast plus axillary node dissection, with the intention of
        giving breast irradiation following completion of an adjuvant chemotherapy regimen Regional
        nodal or chest wall irradiation not prohibited but strongly discouraged No evidence of
        residual tumor in the axilla following dissection No microscopic evidence of residual tumor
        at the resection margins following total mastectomy Further excision highly recommended if
        there is microscopic residual disease present at partial mastectomy margins If further
        excision is not undertaken, a radiotherapy boost to the tumor bed is required in addition
        to breast irradiation given following protocol chemotherapy Disease clinically staged prior
        to surgery as T1-T3a, N0-2, M0 No clinical T4 disease, i.e.: No extension to the chest wall
        No edema (including peau d'orange) No skin ulceration No satellite skin nodules confined to
        the same breast No inflammatory carcinoma Disease pathologically staged following surgery
        as TNM stage I, II, or III (T0-4; N0-2; M0) T4 allowed only with dermal involvement on
        pathology assessment No evidence of metastatic disease beyond the homolateral axillary
        nodes on pre-chemotherapy chest x-ray, bone scan (with radiographs of suspicious areas),
        and abdominal ultrasound (required only if bilirubin, alkaline phosphatase, or AST/ALT are
        elevated) Simultaneous bilateral breast carcinoma allowed Complete tumor resection on both
        breasts required Axillary dissection on both sides must meet criteria as above if both
        sides are clinically node-positive Axillary dissection on the second side optional if the
        axilla is clinically negative at the time of surgery and the other side is node-positive
        Adjuvant chemotherapy must begin within 14 weeks of initial pathologic diagnosis Hormone
        receptor status: Any receptor level allowed (values must be available if biochemical method
        used; immunocytochemical assay permitted)

        PATIENT CHARACTERISTICS: Age: Not specified Sex: Female Menopausal status: Pre- or
        perimenopausal, i.e., meeting at least 1 of the following criteria: Normal menstruation
        Amenorrhea for less than 1 year (up to 3 years in patients under age 52) Biochemical
        evidence of ovarian function Hysterectomy without bilateral oophorectomy in patients under
        age 56 Premenopausal women no greater than age 50 who were started on replacement hormone
        therapy before amenorrhea are eligible Performance status: ECOG 0-2 prior to chemotherapy
        Hematopoietic: WBC at least 3,000/mm3 Polymorphs and bands at least 1,500/mm3 Platelet
        count at least 100,000/mm3 Hepatic: (unless abdominal ultrasound indicates liver
        metastasis) Alkaline phosphatase no greater than 2 times normal AST and/or ALT no greater
        than 2 times normal Renal: Not specified Other: No history of serious underlying medical
        illness or psychiatric or addictive disorder No second malignancy within 5 years except:
        Curatively treated nonmelanomatous skin cancer Curatively treated endometrium, colon, or
        thyroid cancer or carcinoma in situ of the cervix No plan for pregnancy during the 5-year
        study period Fertile women must use effective contraception (other than oral contraception)
        Accessible for treatment and follow-up

        PRIOR CONCURRENT THERAPY: Biologic therapy: Colony-stimulating factors allowed (use must be
        documented) Chemotherapy: No prior chemotherapy No concurrent other cytotoxic therapy
        Endocrine therapy: Adjuvant tamoxifen (20 mg po daily) allowed up to 2 weeks before or
        during adjuvant chemotherapy provided drug is discontinued at randomization No long-term
        prednisone or other hormones Radiotherapy: See Disease Characteristics Surgery: See Disease
        Characteristics
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vivien H.C. Bramwell, MB, BS, PhD, FRCP</last_name>
    <role>Study Chair</role>
    <affiliation>London Health Sciences Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dr. H. Bliss Murphy Cancer Centre</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>AIB 3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Victoria Hospital</name>
      <address>
        <city>Barrie</city>
        <zip>L4M 6M2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William Osler Health Centre, Brampton Memorial</name>
      <address>
        <city>Brampton</city>
        <zip>L6R 3J7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre</name>
      <address>
        <city>Calgary</city>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PEI Cancer Treatment Centre,Queen Elizabeth Hospital</name>
      <address>
        <city>Charlottetown</city>
        <zip>C1A 8T5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QEII Health Sciences Center</name>
      <address>
        <city>Halifax</city>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Centre at Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Regional de Lanaudiere</name>
      <address>
        <city>Joliette</city>
        <zip>J6E 6J2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Centre of Southeastern Ontario at Kingston</name>
      <address>
        <city>Kingston</city>
        <zip>K7L 5P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>L'Hotel-Dieu de Levis</name>
      <address>
        <city>Levis</city>
        <zip>G6V 3Z1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Program</name>
      <address>
        <city>London</city>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Credit Valley Hospital</name>
      <address>
        <city>Mississauga</city>
        <zip>L5M 2N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUM - Hopital Notre-Dame</name>
      <address>
        <city>Montreal</city>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University - Dept. Oncology</name>
      <address>
        <city>Montreal</city>
        <zip>H2W 1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUM - Hotel Dieu du Montreal</name>
      <address>
        <city>Montreal</city>
        <zip>H2W 1T8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUM - Pavillon Saint-Luc</name>
      <address>
        <city>Montreal</city>
        <zip>H3X 3J4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stronach Regional Health Centre at Southlake</name>
      <address>
        <city>Newmarket</city>
        <zip>L3Y 2P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lakeridge Health Oshawa</name>
      <address>
        <city>Oshawa</city>
        <zip>L1G 2B9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Health Research Institute - General Division</name>
      <address>
        <city>Ottawa</city>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penticton Regional Hospital</name>
      <address>
        <city>Penticton</city>
        <zip>V2A 3G6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peterborough Regional Health Centre</name>
      <address>
        <city>Peterborough</city>
        <zip>K9H 7B6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUQ-Pavillon Hotel-Dieu de Quebec</name>
      <address>
        <city>Quebec City</city>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHA-Hopital Du St-Sacrement</name>
      <address>
        <city>Quebec City</city>
        <zip>G1S 4L8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Institute of Cardiology and</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allan Blair Cancer Centre</name>
      <address>
        <city>Regina</city>
        <zip>S4T 7T1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlantic Health Sciences Corporation</name>
      <address>
        <city>Saint John</city>
        <zip>E2L 4L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saskatoon Cancer Centre</name>
      <address>
        <city>Saskatoon</city>
        <zip>S7N 4H4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Algoma District Cancer Program</name>
      <address>
        <city>Sault Ste. Marie</city>
        <zip>P6A 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier universitaire de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niagara Health System</name>
      <address>
        <city>St. Catharines</city>
        <zip>L2R 7C6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Cancer Program of the Hopital Regional</name>
      <address>
        <city>Sudbury</city>
        <zip>P3E 5J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BCCA - Fraser Valley Cancer Centre</name>
      <address>
        <city>Surrey</city>
        <zip>V3V 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thunder Bay Regional Health Science Centre</name>
      <address>
        <city>Thunder Bay</city>
        <zip>P7B 6V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto East General Hospital</name>
      <address>
        <city>Toronto</city>
        <zip>M4C 3E7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odette Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>Toronto</city>
        <zip>M5G 1X5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. Health Network-The Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. Health Network-Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's College Hospital</name>
      <address>
        <city>Toronto</city>
        <zip>M5S 1B2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Health Centre</name>
      <address>
        <city>Toronto</city>
        <zip>M6R 1B5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trillium Health Centre - West Toronto</name>
      <address>
        <city>Toronto</city>
        <zip>M9C 1A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Humber River Regional Hospital</name>
      <address>
        <city>Toronto</city>
        <zip>M9N 1N8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BCCA - Vancouver Cancer Centre</name>
      <address>
        <city>Vancouver</city>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BCCA - Vancouver Island Cancer Centre</name>
      <address>
        <city>Victoria</city>
        <zip>V8R 6V5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Windsor Regional Cancer Centre</name>
      <address>
        <city>Windsor</city>
        <zip>N8W 2X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CancerCare Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Bramwell VHC, Pritchard KI, Tu D, et al.: How compliant are patients with oral hormonal therapies? Data from a randomized, placebo controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (NCIC CTG MA.12). [Abstract] Breast Cancer Res Treat 106 (1): A-3055, 2007.</citation>
  </results_reference>
  <results_reference>
    <citation>Bramwell VH, Pritchard KI, Tu D, et al.: Tamoxifen (T) compared to placebo (P), after adjuvant chemotherapy (CT), in premenopausal women with early breast cancer (EBC): interim results of NCIC-CTG MA.12. [Abstract] J Clin Oncol 25 (Suppl 18): A-547, 2007.</citation>
  </results_reference>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>July 28, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2004</study_first_posted>
  <last_update_submitted>March 21, 2016</last_update_submitted>
  <last_update_submitted_qc>March 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

